Hirotaka Ohki

433 total citations
20 papers, 221 citations indexed

About

Hirotaka Ohki is a scholar working on Physiology, Rheumatology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Hirotaka Ohki has authored 20 papers receiving a total of 221 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Physiology, 6 papers in Rheumatology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Hirotaka Ohki's work include Lysosomal Storage Disorders Research (8 papers), Glycogen Storage Diseases and Myoclonus (4 papers) and Kawasaki Disease and Coronary Complications (3 papers). Hirotaka Ohki is often cited by papers focused on Lysosomal Storage Disorders Research (8 papers), Glycogen Storage Diseases and Myoclonus (4 papers) and Kawasaki Disease and Coronary Complications (3 papers). Hirotaka Ohki collaborates with scholars based in Japan, United States and France. Hirotaka Ohki's co-authors include Masaru Miura, Satoshi Yasukochi, Hiroyuki Matsuura, Toshio Nishikawa, Tsutomu Saji, Eiichi Yamamoto, Makoto Nakazawa, Yoshio Arakaki, Shigeki Yoshiba and Masaaki Satoh and has published in prestigious journals such as The Journal of Pediatrics, Genetics in Medicine and Scandinavian Journal of Gastroenterology.

In The Last Decade

Hirotaka Ohki

17 papers receiving 218 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hirotaka Ohki Japan 7 90 88 66 52 45 20 221
O'Connell Jb United States 10 109 1.2× 215 2.4× 43 0.7× 11 0.2× 17 0.4× 19 300
Duk Hwan Moon South Korea 11 188 2.1× 160 1.8× 53 0.8× 257 4.9× 11 0.2× 36 430
Mahmoud Abdelnabi United States 7 100 1.1× 43 0.5× 21 0.3× 18 0.3× 10 0.2× 111 194
Pierre‐Emmanuel Séguéla France 10 210 2.3× 127 1.4× 184 2.8× 97 1.9× 52 1.2× 41 325
Nader Chebib France 8 26 0.3× 26 0.3× 36 0.5× 95 1.8× 6 0.1× 17 163
Viviana Serra Spain 10 270 3.0× 73 0.8× 155 2.3× 59 1.1× 16 0.4× 23 406
Daniel Lovrić Croatia 7 48 0.5× 71 0.8× 41 0.6× 44 0.8× 14 0.3× 27 161
Giulia Cundari Italy 11 160 1.8× 49 0.6× 19 0.3× 29 0.6× 16 0.4× 25 300
John Wallwork United Kingdom 10 26 0.3× 274 3.1× 111 1.7× 139 2.7× 5 0.1× 13 367
Chattanong Yodwut United States 9 327 3.6× 56 0.6× 34 0.5× 29 0.6× 5 0.1× 14 432

Countries citing papers authored by Hirotaka Ohki

Since Specialization
Citations

This map shows the geographic impact of Hirotaka Ohki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hirotaka Ohki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hirotaka Ohki more than expected).

Fields of papers citing papers by Hirotaka Ohki

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hirotaka Ohki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hirotaka Ohki. The network helps show where Hirotaka Ohki may publish in the future.

Co-authorship network of co-authors of Hirotaka Ohki

This figure shows the co-authorship network connecting the top 25 collaborators of Hirotaka Ohki. A scholar is included among the top collaborators of Hirotaka Ohki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hirotaka Ohki. Hirotaka Ohki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Mori‐Yoshimura, Madoka, et al.. (2024). Efficacy and safety of avalglucosidase alfa in Japanese patients with late-onset and infantile-onset Pompe diseases: A case series from clinical trials. Molecular Genetics and Metabolism Reports. 42. 101163–101163. 1 indexed citations
4.
Kishnani, Priya S., David Kronn, Anaïs Brassier, et al.. (2022). Safety and efficacy of avalglucosidase alfa in individuals with infantile-onset Pompe disease enrolled in the phase 2, open-label Mini-COMET study: The 6-month primary analysis report. Genetics in Medicine. 25(2). 100328–100328. 28 indexed citations
5.
6.
Kronn, David, James Davison, Anaïs Brassier, et al.. (2022). OP016: Mini-COMET: Safety and efficacy of ≥97 weeks’ avalglucosidase alfa in infantile-onset Pompe disease participants previously treated with alglucosidase alfa. Genetics in Medicine. 24(3). S348–S349. 6 indexed citations
7.
Davison, James, Anaïs Brassier, Alexander Broomfield, et al.. (2021). Mini-COMET study: Effects of repeat avalglucosidase alfa dosing on ptosis in participants with infantile-onset Pompe disease (IOPD) who were previously treated with alglucosidase alfa. Molecular Genetics and Metabolism. 132(2). S31–S32. 1 indexed citations
8.
Kishnani, Priya S., Alexander Broomfield, James Davison, et al.. (2021). Mini-COMET: Individual-level treatment responses in infantile-onset Pompe disease participants receiving avalglucosidase alfa or alglucosidase alfa who previously received alglucosidase alfa. Molecular Genetics and Metabolism. 132. S75–S76. 1 indexed citations
9.
10.
Ejima, Koichiro, Morio Shoda, Hisashi Sugiyama, et al.. (2020). Efficacy of catheter ablation for patients with atrial fibrillation and atrial septal defect. Journal of Cardiovascular Electrophysiology. 32(2). 279–286. 5 indexed citations
11.
Nishino, Ichizo, et al.. (2016). Hypertrophic Cardiomyopathy Associated with Nemaline Myopathy Due to <i>ACTA1</i> Mutation. 32(2). 181–186. 2 indexed citations
12.
Saito, Mika, Naoya Fukushima, Hirotaka Ohki, et al.. (2014). Clinical Study of 11 Patients with Double Aortic Arch. 30(1). 59–63.
13.
Saji, Tsutomu, Hiroyuki Matsuura, Toshio Nishikawa, et al.. (2012). Comparison of the Clinical Presentation, Treatment, and Outcome of Fulminant and Acute Myocarditis in Children. Circulation Journal. 76(5). 1222–1228. 71 indexed citations
14.
Miura, Masaru, et al.. (2011). Steroid pulse therapy for Kawasaki disease unresponsive to additional immunoglobulin therapy. Paediatrics & Child Health. 16(8). 479–484. 23 indexed citations
15.
Miura, Masaru, et al.. (2011). Life-threatening atrial tachycardia after the Senning operation in a patient with transposition of the great arteries. Heart and Vessels. 27(4). 424–427. 5 indexed citations
16.
Yoshihashi, Hiroshi, Hirotaka Ohki, Chiharu Torii, Akira Ishiko, & Kenjiro Kosaki. (2010). Survival of a Male Mosaic for PORCN Mutation with Mild Focal Dermal Hypoplasia Phenotype. Pediatric Dermatology. 28(5). 550–554. 7 indexed citations
17.
Miura, Masaru, et al.. (2008). Effects of methylprednisolone pulse on cytokine levels in Kawasaki disease patients unresponsive to intravenous immunoglobulin. European Journal of Pediatrics. 167(10). 1119–1123. 34 indexed citations
18.
Miura, Masaru, et al.. (2008). [Methylprednisolone pulse therapy in Kawasaki disease].. PubMed. 66(2). 338–42. 1 indexed citations
19.
Morishima, Itsuro, Takashi Kumada, Shogo Nakano, et al.. (1995). Serum Levels of Soluble Interleukin-2 Receptor in Chronic Hepatitis C Treated with Interferon-Alpha. Scandinavian Journal of Gastroenterology. 30(8). 807–811. 6 indexed citations
20.
Toyoda, Hidenori, Ikuko Takeda, Takashi Kumada, et al.. (1994). Retreatment of chronic hepatitis C with interferon.. PubMed. 89(9). 1453–7. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by O'Connell Jb Breakdown of academic impact, for papers by Duk Hwan Moon Breakdown of academic impact, for papers by Mahmoud Abdelnabi Breakdown of academic impact, for papers by Pierre‐Emmanuel Séguéla Breakdown of academic impact, for papers by Nader Chebib Breakdown of academic impact, for papers by Viviana Serra Breakdown of academic impact, for papers by Daniel Lovrić Breakdown of academic impact, for papers by Giulia Cundari Breakdown of academic impact, for papers by John Wallwork Breakdown of academic impact, for papers by Chattanong Yodwut
Rankless by CCL
2026